The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib (Q81604961)
Jump to navigation
Jump to search
scientific article published on 01 April 2005
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib |
scientific article published on 01 April 2005 |
Statements
The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients (English)
Pauline Breedveld
Dick Pluim
Greta Cipriani
Peter Wielinga
Olaf van Tellingen
Alfred H Schinkel